Multiple Sclerosis and Related Disorders

Journal

Publication Venue For

  • COVID-19 in the pregnant or postpartum MS patient: Symptoms and outcomes.  65. 2022
  • Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases.  63. 2022
  • The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions.  61. 2022
  • Do physical activity, cardiorespiratory fitness, and subcortical brain structures explain reduced walking performance in older adults with multiple sclerosis?.  60. 2022
  • Measuring cognitive function by the SDMT across functional domains: Useful but not sufficient.  60. 2022
  • Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies.  60. 2022
  • AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.  57. 2022
  • White matter tracts that overlap with the thalamus and the putamen are protected against multiple sclerosis pathology.  57. 2022
  • Demographic, clinical, and symptomatic correlates of subjective sleep quality in adults with multiple sclerosis.  55. 2021
  • Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional study.  50. 2021
  • CSF plasmablasts differentiate MS from other neurologic disorders.  48. 2021
  • A longitudinal study of symptom botheration in Multiple Sclerosis..  46. 2020
  • Effect size – one size doesn't fit all.  46. 2020
  • Feasibility of improving dietary quality using a telehealth lifestyle intervention for adults with multiple sclerosis.  46. 2020
  • Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD.  40. 2020
  • EFFECT size or statistical significance, where to put your money.  38. 2020
  • The priorities of neurologists for exercise promotion in comprehensive multiple sclerosis care.  38. 2020
  • Gender identity and sexual orientation affect health care satisfaction, but not utilization, in persons with Multiple Sclerosis.  37. 2020
  • Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.  33:13-21. 2019
  • Evaluation of a web-based fall prevention program among people with multiple sclerosis.  31:151-156. 2019
  • The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments.  31:165-172. 2019
  • Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes.  29:86-93. 2019
  • Use of eHealth and mHealth technology by persons with multiple sclerosis.  27:13-19. 2019
  • An introduction to Mendelian randomization with applications in neurology.  24:72-78. 2018
  • A survey of dietary characteristics in a large population of people with multiple sclerosis.  22:12-18. 2018
  • Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis.  22:103-107. 2018
  • Factors associated with excessive sitting time in multiple sclerosis.  21:71-77. 2018
  • Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis.  20:16-21. 2018
  • Examining the contributions of environmental quality to pediatric multiple sclerosis.  18:164-169. 2017
  • Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.  18:95-102. 2017
  • Upper limb impairment is associated with use of assistive devices and unemployment in multiple sclerosis.  13:87-92. 2017
  • Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.  12:70-78. 2017
  • A case-control study of dietary salt intake in pediatric-onset multiple sclerosis.  6:87-92. 2016
  • Relapses in multiple sclerosis: Relationship to disability.  6:10-20. 2016
  • Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database.  4:546-554. 2015
  • Causes of death among persons with multiple sclerosis.  4:484-490. 2015
  • Impact of multiple sclerosis relapse: The NARCOMS participant perspective.  4:234-240. 2015
  • Risk tolerance to MS therapies: Survey results from the NARCOMS registry.  4:241-249. 2015
  • Regional gray matter atrophy in relapsing remitting multiple sclerosis: Baseline analysis of multi-center data.  4:124-136. 2015
  • Bifactor structure of clinical disability in relapsing multiple sclerosis.  3:176-185. 2014
  • Improvement of multiple sclerosis-associated tremor as a treatment effect of natalizumab.  3:505-512. 2014
  • Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.  3:705-711. 2014
  • Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S..  3:364-371. 2014
  • A retrospective review of lithium usage in veterans with multiple sclerosis.  2:327-333. 2013
  • Substantial burden of dizziness in multiple sclerosis.  2:21-28. 2013
  • The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: Design and baseline characteristics..  1:81-86. 2012
  • The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics.  1:81-86. 2012
  • International Standard Serial Number (issn)

  • 2211-0348
  • Electronic International Standard Serial Number (eissn)

  • 2211-0356